The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ri is selected from an SCN- group or is an RCONH- group in particular, where Ri = RCONH, R is selected from an aromatic benzene ring substituted with an SCN- group in the ortho, meta or para position, according to the following formula: SCN- or R is a C1 -C4 alkyl chain, substituted with an SCN- group n can be equal to 0 or else 1. The invention also relates to the use of such compounds for the treatment of osteoporosis and in general of bone pathologies characterised by a progressive loss of bone mass, for example rheumatoid arthritis, hyperparathyroidism or bone tumour metastases
